Literature DB >> 22198790

Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis.

Russell R Kempker1, Alexander S Rabin, Ketino Nikolaishvili, Iagor Kalandadze, Shota Gogishvili, Henry M Blumberg, Sergo Vashakidze.   

Abstract

The pathogenesis of increasing drug resistance among patients with multidrug-resistant or extensively drug-resistant tuberculosis undergoing treatment is poorly understood. Increasing drug resistance found among Mycobacterium tuberculosis recovered from cavitary isolates compared with paired sputum isolates suggests pulmonary cavities may play a role in the development of worsening tuberculosis drug resistance.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22198790      PMCID： PMC3284212          DOI： 10.1093/cid/cir904

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  8 in total

1.  The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection.

Authors:  H M VANDIVIERE; W E LORING; I MELVIN; S WILLIS
Journal:  Am J Med Sci       Date:  1956-07       Impact factor: 2.378

2.  Genetic polymorphism in Mycobacterium tuberculosis isolates from patients with chronic multidrug-resistant tuberculosis.

Authors:  Frank A Post; Paul A Willcox; Barun Mathema; Lafras M Steyn; Karen Shean; Srinivas V Ramaswamy; Edward A Graviss; Elena Shashkina; Barry N Kreiswirth; Gilla Kaplan
Journal:  J Infect Dis       Date:  2004-05-28       Impact factor: 5.226

3.  Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis.

Authors:  Neel R Gandhi; Paul Nunn; Keertan Dheda; H Simon Schaaf; Matteo Zignol; Dick van Soolingen; Paul Jensen; Jaime Bayona
Journal:  Lancet       Date:  2010-05-22       Impact factor: 79.321

4.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

Review 5.  Pulmonary resection for patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.

Authors:  Hong-Bin Xu; Rui-Hua Jiang; Ling Li
Journal:  J Antimicrob Chemother       Date:  2011-06-03       Impact factor: 5.790

Review 6.  Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis.

Authors:  Véronique Dartois; Clifton E Barry
Journal:  Curr Clin Pharmacol       Date:  2010-05

Review 7.  Mechanisms of drug resistance in Mycobacterium tuberculosis.

Authors:  Y Zhang; W W Yew
Journal:  Int J Tuberc Lung Dis       Date:  2009-11       Impact factor: 2.373

8.  Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity.

Authors:  Gilla Kaplan; Frank A Post; Andre L Moreira; Helen Wainwright; Barry N Kreiswirth; Melike Tanverdi; Barun Mathema; Srinivas V Ramaswamy; Gabi Walther; Lafras M Steyn; Clifton E Barry; Linda-Gail Bekker
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441
  8 in total
  33 in total

1.  Syntheses and evaluation of substituted aromatic hydroxamates and hydroxamic acids that target Mycobacterium tuberculosis.

Authors:  Mark W Majewski; Sanghyun Cho; Patricia A Miller; Scott G Franzblau; Marvin J Miller
Journal:  Bioorg Med Chem Lett       Date:  2015-05-20       Impact factor: 2.823

Review 2.  The medical and surgical treatment of drug-resistant tuberculosis.

Authors:  Gregory L Calligaro; Loven Moodley; Greg Symons; Keertan Dheda
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

3.  Comparison of the characteristics of Mycobacterium tuberculosis isolates from sputum and lung lesions in chronic tuberculosis patients.

Authors:  M-S Hong; Y Kim; E-J Cho; J-S Lee; H-K Kwak; J-H Kim; C-T Kim; J-S Cho; S-K Park; D Jeon; Y-I Choi; H Lee; S-Y Eum
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-06-15       Impact factor: 3.267

4.  High-dose vitamin D3 in adults with pulmonary tuberculosis: a double-blind randomized controlled trial.

Authors:  Nestan Tukvadze; Ekaterina Sanikidze; Maia Kipiani; Gautam Hebbar; Kirk A Easley; Neeta Shenvi; Russell R Kempker; Jennifer K Frediani; Veriko Mirtskhulava; Jessica A Alvarez; Nino Lomtadze; Lamara Vashakidze; Li Hao; Carlos Del Rio; Vin Tangpricha; Henry M Blumberg; Thomas R Ziegler
Journal:  Am J Clin Nutr       Date:  2015-09-23       Impact factor: 7.045

Review 5.  Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis.

Authors:  Anca Dorhoi; Stefan H E Kaufmann
Journal:  Semin Immunopathol       Date:  2015-10-05       Impact factor: 9.623

6.  A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis.

Authors:  Russell R Kempker; M Tobias Heinrichs; Ketino Nikolaishvili; Irina Sabulua; Nino Bablishvili; Shota Gogishvili; Zaza Avaliani; Brent P Little; Adam Bernheim; Hartmut Derendorf; Henry M Blumberg; Sergo Vashakidze; Charles A Peloquin
Journal:  Eur Respir J       Date:  2018-02-07       Impact factor: 16.671

7.  Tuberculosis, pulmonary cavitation, and matrix metalloproteinases.

Authors:  Catherine W M Ong; Paul T Elkington; Jon S Friedland
Journal:  Am J Respir Crit Care Med       Date:  2014-07-01       Impact factor: 21.405

8.  Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis.

Authors:  Keertan Dheda; Laura Lenders; Gesham Magombedze; Shashikant Srivastava; Prithvi Raj; Erland Arning; Paula Ashcraft; Teodoro Bottiglieri; Helen Wainwright; Timothy Pennel; Anthony Linegar; Loven Moodley; Anil Pooran; Jotam G Pasipanodya; Frederick A Sirgel; Paul D van Helden; Edward Wakeland; Robin M Warren; Tawanda Gumbo
Journal:  Am J Respir Crit Care Med       Date:  2018-11-01       Impact factor: 21.405

Review 9.  Cavitary tuberculosis: the gateway of disease transmission.

Authors:  Michael E Urbanowski; Alvaro A Ordonez; Camilo A Ruiz-Bedoya; Sanjay K Jain; William R Bishai
Journal:  Lancet Infect Dis       Date:  2020-05-05       Impact factor: 25.071

10.  Favorable outcomes for multidrug and extensively drug resistant tuberculosis patients undergoing surgery.

Authors:  Sergo Vashakidze; Shota Gogishvili; Ketino Nikolaishvili; Nino Dzidzikashvili; Nestani Tukvadze; Henry M Blumberg; Russell R Kempker
Journal:  Ann Thorac Surg       Date:  2013-05-01       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.